Breast Cancer Drugs In The Pipeline

News — By on December 12, 2008 at 7:00 am

Scientists in the clinic and the laboratory continue to work to drive breast cancer mortality rates down with breakthrough drugs. With tamoxifen’s discovery 30 years behind us, and the impact of Herceptin still being felt, researchers are studying zoledronic acid, aromatase inhibitors and monoclonal antibodies, among others, with encouraging results. Data was presented at the CTRC-AACR San Antonio Breast Cancer Symposium.

Please read the complete article and let us know what you think below.

Leave a Reply


Leave a Trackback